Dataset Information


MiR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma.

ABSTRACT: A number of studies suggest an association between miRNAs and diffuse large B-cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value of microRNA (miR-150) in primary gastrointestinal (PGI)-DLBCL, by assessing the association between miR-150 expression and clinicopathological characteristics in patients with PGI-DLBCL. A total of 84 patients diagnosed with PGI-DLBCL were recruited and both tumor and adjacent non-tumor tissue samples were collected. miR-150 expression was assessed via reverse transcription-quantitative (RT-q)PCR analysis. The results demonstrated that miR-150 expression was significantly lower in PGI-DLBCL tissues compared with adjacent non-tumor tissues. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that the optimal cut-off value of miR-150 for predicting survival was 8.965 with high sensitivity (79.8%) and specificity (77.1%). Patients were divided into two groups according to this cut-off value, as follows: High (n=18) and low expression (n=66) groups. Low miR-150 expression was significantly associated with clinical stage, International Prognostic Index (IPI), Eastern Cooperative Oncology Group status and use of rituximab. RT-qPCR analysis demonstrated that miR-150 expression was significantly lower in patients with high IPI scores compared with patients with low IPI scores. Downregulated miR-150 expression was significantly associated with shorter overall survival (OS) time and progression-free survival (PFS) time in patients with PGI-DLBCL. Furthermore, miR-150 level and IPI score were identified as two risk factors for OS and PFS. The diagnostic value of miR-150 was evaluated via ROC curve analysis, with an area under the curve value of 0.882. Taken together, the results of the present study suggest that miR-150 is a potential diagnostic marker of PGI-DLBCL, and may also serve as a useful prognostic factor for survival outcomes in patients with PGI-DLBCL.


PROVIDER: S-EPMC7115130 | BioStudies | 2020-01-01

SECONDARY ACCESSION(S): 10.6004/jnccn.2016.0117

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7439117 | BioStudies
2020-01-01 | S-EPMC7082970 | BioStudies
2017-01-01 | S-EPMC5646333 | BioStudies
2011-01-01 | S-EPMC3117929 | BioStudies
2012-01-01 | S-EPMC3681505 | BioStudies
2015-01-01 | S-EPMC4431801 | BioStudies
1000-01-01 | S-EPMC3152499 | BioStudies
2019-01-01 | S-EPMC6849243 | BioStudies
1000-01-01 | S-EPMC5773951 | BioStudies
2017-01-01 | S-EPMC5537331 | BioStudies